AMGN vs EW
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions.
Side-by-side fundamentals
| Metric | AMGN | EW | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $358.32 | $87.27 | |
| Market cap as of 2026-07-16 | $192.4B | $50.9B | |
| P/E as of 2026-07-16 | 24.67 | 46.42 | AMGN lower |
| PEG as of 2026-07-16 | 4.93 | 2.13 | EW lower |
| Net margin as of 2026-07-16 | +21.0% | +17.4% | AMGN higher |
| Gross margin as of 2026-07-16 | +74.0% | +77.9% | EW higher |
| Operating margin as of 2026-07-16 | +28.8% | +17.1% | AMGN higher |
| ROE as of 2026-07-16 | +89.4% | +10.6% | AMGN higher |
| ROA as of 2026-07-16 | +8.6% | +8.2% | AMGN higher |
| Debt / equity as of 2026-07-16 | 6.24 | 0.06 | EW lower |
| Revenue growth (YoY) as of 2026-07-16 | +9.1% | +13.8% | EW higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +10.8% | AMGN higher |
| Dividend yield as of 2026-07-16 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-16 | 0.43 | 0.83 | |
| 1-year return as of 2026-07-15 close | +19.6% | +15.1% | AMGN higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.